Kidney Diseases
Conditions
Brief summary
An open-label, Phase II, multi-center study evaluating multiple doses of DM199 in participants with chronic kidney disease.
Detailed description
This is an open-label, Phase II, multi-center study evaluating DM199 in approximately 90 Participants in three cohorts. Cohort I: African Americans with CKD (Stage II or III), hypertension and non-diabetic Cohort II: Participants with IgA nephropathy diagnosis and CKD (Stage II or III) Cohort III: Diabetes Mellitus (Type II) with CKD (Stage II or III) and hypertension Participants in each cohort will be enrolled in a parallel assignment to one of two doses: Dose 1: DM199 2.0 µg/kg SC 2x week for 95 days Dose 2: DM199 5.0 µg/kg SC 2x week for 95 days
Interventions
DRUGDM199
A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
Sponsors
DiaMedica Therapeutics Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Cohort I * African American * Hypertension as defined by the American Heart Association for Stage I hypertension where systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥ 80 mmHg or on medication for treatment of hypertension. Cohort II * IgA nephropathy confirmed by medical history with biopsy Cohort III * Diabetes Mellitus (Type 2) with hypertension where systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥ 80 mmHg or on medication for treatment of hypertension * Hemoglobin A1c ≥7% at screening Both Cohorts * Participant is willing and able to provide informed consent for study participation * Participant male or female ≥ 18 years of age * Participant has CKD as defined by using CKD EPI for Stage II 60 to \<90 mL/min/1.73 m2 or Stage III 30 to \<60 mL/min/1.73 m2 * UACR \>150 mg/g and \<5000 mg/g at screening * Participant is clinically stable with respect to underlying renal impairment as assessed by the Investigator's medical evaluation
Exclusion criteria
* Participant has positive drug test for drugs of abuse and/or positive alcohol breath test at screening and Day 1 * Participant has a current diagnosis and/or is taking medication or diet control for diabetes (cohort I and II only) * Participant has an A1c \> 7% at screening (cohort I and II only) * Participant received corticosteroid therapy within last 3 months * Participant is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits * Participant has a history of significant allergic diathesis such as urticaria, angioedema, or anaphylaxis * Participant has been previously diagnosed with kidney disease other than for hypertension, IgA or Diabetes Mellitus (Type II) * Participant has hypotension as defined by systolic blood pressure ≤ 90 mmHg and diastolic blood pressure ≤ 60 mmHg at screen * ACEi or GLP-1 medication prescribed for and taken by Participant (must not be taking for 5 half-lives prior to study drug administration and for 10 days post study drug administration) * Participant has a current malignancy or active malignancy ≤ 2 years prior to enrollment except basal cell or squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy and ≥ 6 months have elapsed since the procedure * Participant has an active infection at the time of enrollment, and/or a history of clinically significant acute bacterial, viral, or fungal systemic infections that required systemic treatment with a completed therapy in the last 7 days prior to enrollment * Participant has known medical history of alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency) * Participant is pregnant or nursing or is planning a pregnancy during the study period * Participant is male or female of childbearing potential, is participating in sexual activity that could lead to pregnancy and is unable or unwilling to practice medically effective contraception during the study * Participant has received any investigational drug or device within 14 days (or 5 half lives, whichever is longer) prior to study drug administration starting on Day 1 * Participant has renal artery stenosis as determined at screen with medical history * Participant received a kidney transplant * Participant does not have adequate venous access for blood sampling * Participant has any other medical condition which, in the opinion of the Investigator, will make participation medically unsafe or interfere with the study results * Participant has any other clinically significant abnormalities in laboratory test results at screening that would, in the opinion of the Investigator, increase the Participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data * Participant has any significant arrhythmia or conduction abnormality, which in the opinion of the Investigators and Medical Monitor may interfere with the safety of the Participant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment emergent adverse events | 12 weeks | Incidence, severity, and causality of adverse events |
| Change in renal function | 12 weeks | eGFR |
| Change in urine albumin to creatinine ratio | 12 weeks | UACR change from baseline |
| Plasma measurements of DM199 | 12 weeks | Maximum plasma concentration of DM199 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cystatin C concentration in plasma, change from baseline | 12 weeks | Cystatin C change from baseline |
| Tumor necrosis factor receptor 1 (TNF R1) concentration in plasma, change from baseline | 12 weeks | TNF R1 change from baseline |
| Prostacyclin concentration in plasma, change from baseline | 12 weeks | Prostacyclin change from baseline |
| Prostaglandin E2 concentration in plasma, change from baseline | 12 weeks | Prostaglandin E2 change from baseline |
| C-reactive protein (CRP) concentration in plasma, change from baseline | 12 weeks | CRP change from baseline |
| Matrix metalloproteainase-9 (MMP-9) concentration in plasma, change from baseline | 12 weeks | MMP-9 change from baseline |
| Vascular endothelial growth factor (VEGF) concentration in plasma, change from baseline | 12 weeks | VEGF change from baseline |
Countries
United States
Outcome results
None listed